Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.
Academies and Institutes
/ standards
Biomedical Research
/ organization & administration
Cancer Care Facilities
/ organization & administration
Cohort Studies
Europe
/ epidemiology
Humans
Medical Oncology
/ standards
Neoplasms
/ epidemiology
Patient Care Team
/ organization & administration
Patient-Centered Care
/ organization & administration
Quality of Health Care
Translational Research, Biomedical
/ methods
accreditation
clinical trials
comprehensive cancer center
multidisciplinarity
quality standard
translational research
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
06
03
2021
received:
05
01
2021
accepted:
17
03
2021
pubmed:
19
3
2021
medline:
1
4
2022
entrez:
18
3
2021
Statut:
ppublish
Résumé
There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
Identifiants
pubmed: 33734563
doi: 10.1002/1878-0261.12950
pmc: PMC8096787
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1277-1288Informations de copyright
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Tumori. 2015;101 Suppl 1:S6-9
pubmed: 27098181
Mol Oncol. 2009 Jun;3(3):192-203
pubmed: 19393582
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Lancet Oncol. 2020 Aug;21(8):1009-1011
pubmed: 32758458
Mol Oncol. 2020 Aug;14(8):1589-1615
pubmed: 32749074
Br J Surg. 2018 Dec;105(13):1807-1815
pubmed: 30132789
Eur J Cancer. 2018 Apr;93:138-139
pubmed: 29454744
Mol Oncol. 2019 Mar;13(3):502-510
pubmed: 30657635
Am Soc Clin Oncol Educ Book. 2016;35:185-98
pubmed: 27249699
J Cancer Res Clin Oncol. 2016 Jun;142(6):1353-60
pubmed: 26995276
Ann Surg. 2005 Oct;242(4):540-4; discussion 544-7
pubmed: 16192814
JAMA Intern Med. 2019 Aug 1;179(8):1043-1051
pubmed: 31206142
Mol Oncol. 2019 Nov;13(11):2301-2304
pubmed: 31670486
J Oncol Pract. 2014 Sep;10(5):e342-9
pubmed: 25118210
J Am Coll Surg. 2015 May;220(5):940-50
pubmed: 25840536
Cancer. 2005 Feb 1;103(3):435-41
pubmed: 15622523
BMC Cancer. 2017 Dec 14;17(1):850
pubmed: 29241445
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
JAMA Oncol. 2015 Dec;1(9):1303-10
pubmed: 26448610
Tumori. 2019 Dec;105(6):447-455
pubmed: 31718477
Nat Rev Cancer. 2001 Dec;1(3):240-5
pubmed: 11902579
JAMA. 1998 Nov 25;280(20):1747-51
pubmed: 9842949
Cancer. 2015 Nov 1;121(21):3885-93
pubmed: 26218755
Mol Oncol. 2019 Mar;13(3):614-618
pubmed: 30628155